Example: Heart Attack

Search clinical trials for: Modulation of FiO2

Total 10000 results

NCT04466917

Withdrawn

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
NCT01754857

Completed

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Lymphoma, Non-Hodgkin | Small Lymphocytic Lymphoma | Lymphoid Leukemia
NCT02829931

Completed

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Malignant Glioma
NCT00553800

Completed

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
NCT03126799

Active, not recruiting

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) (AvaTa)

EGFR Positive Non-small Cell Lung Cancer
NCT00321100

Terminated

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Colorectal Neoplasms
NCT02959554

Terminated

Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control (NIVOSWITCH)

Metastatic Renal Cell Carcinoma
NCT01185366

Terminated

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Kidney Cancer
NCT03380689

Withdrawn

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer (SIRB2)

Metastatic Colorectal Cancer
NCT01146795

Completed

Neoadjuvant Therapy for Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer
NCT04483830

Completed

Suloexide in the Treatment of Early Stages of COVID-19 (SulES-COVID)

Covid19
NCT00729118

Completed

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm
NCT01831089

Completed

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Head and Neck Carcinoma | Gynecological Cancer | Non-squamous Cell Lung Cancer
NCT03311321

Unknown

Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients

Cardiovascular Diseases | Hemodialysis | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Vitamin K Deficiency
NCT01502228

Terminated

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma
NCT03271255

Unknown

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Gastrointestinal Neoplasms | Digestive System Neoplasms | Colorectal Neoplasms | Intestinal Neoplasms
NCT01740154

Terminated

Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Fatigue | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer
NCT01002157

Unknown

The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification (VitaK-CAC)

Coronary Artery Disease
NCT00463060

Completed

Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Cancer
NCT00881751

Completed

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Liver Cancer
NCT01051934

Completed

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Adenocarcinoma | Non-Small Cell Lung Cancer
NCT02023710

Unknown

Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma

Melanoma
NCT03095001

Unknown

Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion

Peritoneal Adhesion
NCT00642759

Completed

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
NCT00730353

Completed

Sutent + Taxol for Advanced Esophageal Cancer

Esophageal Cancer
NCT01493505

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer
NCT02928575

Unknown

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Glioblastoma Multiforme
NCT00741221

Completed

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

Non-small-cell Lung Cancer
NCT01428713

Completed

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

Menorrhagia
NCT00193375

Completed

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Lung Cancer
NCT02778893

Unknown

Conmana Combined With Thalidomide to Treat NSCLC

NSCLC
NCT00257608

Completed

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Non-Small Cell Lung Cancer
NCT01069796

Terminated

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Triple Negative Metastatic Breast Cancer
NCT00588237

Completed

Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary PERITONEUM
NCT00945139

Completed

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Ovarian Cancer
NCT01760746

Completed

Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis (Humour)

Proliferative Diabetic Retinopathy (PDR)
NCT00904839

Completed

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Colorectal Neoplasms
NCT01674738

Withdrawn

TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV (SELECT-A)

Carcinoma, Non-Small-Cell Lung
NCT01238055

Completed

Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

Advanced Gastric Cancer
NCT00735436

Terminated

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme | Malignant Glioma | Gliosarcoma
NCT01022918

Completed

Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma (TemAvIr)

Naive Unresectable Glioblastoma
NCT00795171

Unknown

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Hormone Refractory Prostate Cancer
NCT00308529

Completed

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

Lung Cancer | Carcinoma, Small Cell Lung
NCT00006257

Completed

SU5416 and Paclitaxel in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific
NCT01019798

Unknown

Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

Non Small Cell Lung Cancer
NCT00179699

Terminated

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
NCT06722586

Recruiting

Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia (SMART)

Thrombocytopaenia | Antiphospholipid (aPL)-Positive
NCT06521255

Recruiting

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

DLBCL
NCT06360042

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma
NCT05556798

Active, not recruiting

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Multiple Myeloma

Search clinical trials for: Modulation of FiO2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations